Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cutaneous adverse reactions to anti-PD-1 treatment - a systematic review

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Risk of systemic infections in adults with atopic dermatitis: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Factors associated with citation of original articles in 5 high-impact-factor dermatology journals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The use of the humanized monoclonal anti-programmed cell death-1 antibodies pembrolizumab and nivolumab as potent anti-cancer therapies is rapidly increasing. However, since their approval numerous cases of cutaneous reactions have been reported. Cutaneous adverse reactions to these agents have yet to be fully characterized and range from non-specific eruptions to recognizable skin manifestations, which may be localized and vary from mild to life-threatening. This systematic review article provides an overview of the various adverse cutaneous reactions to pembrolizumab and nivolumab therapy and offers suggestions for their management.

OriginalsprogEngelsk
TidsskriftJournal of the American Academy of Dermatology
Vol/bind83
Udgave nummer5
Sider (fra-til)1415-1424
Antal sider10
ISSN0190-9622
DOI
StatusUdgivet - 1 nov. 2020

ID: 59742095